Patient groups are a potent force in the Duchenne muscular dystrophy field, where parents are known to take a vocal role in pushing regulators to help biotechs advance new therapies for the lethal genetic condition. Now one of those parents, J.P. Morgan vet Ilan Ganot, has reportedly been raising some serious cash to do deals on early-stage therapies that can be rushed through clinical development.
Novartis said its in-development skin cancer drug aced a Phase II study, completely eradicating the disease in some patients, and now the company plans to loop in regulators, possibly signaling an early FDA application for the treatment.
LONDON--AstraZeneca's top brass can't wait to start rubbing shoulders with scientists at its planned corporate campus in Cambridge, U.K. So the pharma giant has opted to send an advance team of scientists ahead to get the creative juices flowing early on.
To regenerate tissue such as cartilage in the body using stem cells, researchers at Duke University have created a system using a scaffold to deliver gene therapy with built-in growth factors that allow for a programmed regenerative response.
After a high-profile breast cancer failure bit into its potential sales, Eli Lilly's ramucirumab aced a Phase III study in lung cancer, renewing hopes that the star of the drugmaker's oncology pipeline can still deliver on its promise.
AdvaMed has surveyed its members about the medical device excise tax that ObamaCare ushered in last year. No surprise: The med tech industry trade group found companies reported job losses, R&D cuts and slackening investment in U.S. manufacturing.
Cambridge, MA's Akebia Therapeutics is lining up for a $75 million Wall Street debut, looking to raise cash and get its promising anemia drug into late-stage development.
At issue: Decision's Shasta GenStrip, a disposable glucose test strip that is designed to work with J&J's LifeScan Ultra glucose testing meters.
Tokyo drug developer RegImmune has banked $9.2 million in Series D financing to bankroll early-stage products using the company's immune system-regulating platform.
GlaxoSmithKline is looking to deepen its respiratory pipeline with another late-stage trial of the injectable mepolizumab, this time studying the drug's effects in a rare inflammatory disease that can be life-threatening.